<DOC>
	<DOCNO>NCT00305370</DOCNO>
	<brief_summary>There scarcity clinical trial assess effect medication child bipolar disorder . This study aim assess efficacy Aripiprazole associate Methylphenidate ( MPH ) treatment child adolescent bipolar disorder comorbid ADHD improve maniac symptom receive aripiprazole adequate response ADHD symptom . The study design 4-week randomized , double blind , cross-over group trial . Patients randomized aripiprazole + MPH aripiprazole + placebo . The main hypothesis : Aripiprazole + MPH significantly reduce ADHD score compare aripiprazole + placebo .</brief_summary>
	<brief_title>Aripiprazole Associated With Methylphenidate Children Adolescents With Bipolar Disorder ADHD</brief_title>
	<detailed_description>Bipolar disorder ( BD ) chronic disorder severely affect normal development child adolescent . The disorder associate high rate suicide high-risk behavior like sexual promiscuity drug abuse . Bipolar disorder child also associate high rate comorbidity , especially Attention-Deficit Hyperactivity Disorder ( ADHD ) . There scarcity clinical trial assess effect medication child BD . Moreover , frequent presence comorbid ADHD might determine low response treatment . Aripiprazole novel anti-psychotic drug . Its mechanism action seem related stabilization dopaminergic transmission , act partial agonist especially dopaminergic D2 receptor . It also effect 5-HT1a serotonergic receptor . Thus , might promise effect child adolescent comorbid BD ADHD . A retrospective chart review , recently publish , suggest efficacy drug child BD . This study aim assess efficacy Aripiprazole associate Methylphenidate ( MPH ) treatment 20 child adolescent ( age range : 8 17 years-old ) Bipolar Disorder comorbid ADHD improve maniac symptom receive aripiprazole adequate response ADHD symptom . The study design 4-week randomized , double blind , cross-over group trial . Patients randomized aripiprazole + MPH aripiprazole + placebo . The hypothesis : 1 ) Aripiprazole + MPH significantly reduce ADHD score compare aripiprazole + placebo . 2 ) Patients receive aripiprazole + MPH deteriorate maniac symptom .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Age : 8 17 BD type I II comorbid ADHD Reduction maniac symptom ( 30 % reduction YMRS score and/or CGI score â‰¤ 2 ) use aripiprazole previous study ( NCT00116259 ) without improvement ADHD symptom ( reduction ADHD symptom &lt; 30 % SNAPIV ) . Those receive placebo previous protocol receive 6 week open label treatment aripiprazole . The threshold reducing maniac symptom absence response ADHD symptom use . IQ &lt; 70 Pregnancy absence contraceptive method fertile girl Diagnoses : pervasive development disorder , schizophrenia , drug abuse dependency Risk suicide homicide Clinical condition might interfere study Known sensibility aripiprazole</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>clinical trial</keyword>
	<keyword>aripiprazole</keyword>
	<keyword>methylphenidate</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Attention-Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
</DOC>